[Evaluation of initial results of treatment of lead poisoning with EDTA].
The results of EDTA therapy were studied in 37 workers of a battery factory consisting of males with varying degrees of occupational lead poisoning (low exposure: 10 subjects, blood lead levels (PbB) lower than 400 micrograms/l with slight alterations in heme biosynthesis; beyond limit of effect: 5 subjects, PbB > 400 micrograms/l; slight intoxication: 19 subjects, with marked alterations in heme synthesis and preclinical signs of intoxication; average degree of intoxication: 3 subjects with clinical signs of intoxication. Clinical symptoms and the following parameters were investigated: blood lead (PbB), delta-aminolevulinic acid dehydratase in erythrocytes (ALA-D), zinc protoporphyrin (PP) in erythrocytes and delta-aminolevulinic acid (ALA) in 24-hour urine before and after EDTA chelating therapy. Simultaneous measurement of ALA-D and PP showed high diagnostic sensitivity in detecting lead poisoning in occupationally exposed subjects. In view of the high interindividual variability of the results, these indices did not, however, permit a useful differentiation to be made of the different degrees of intoxication at individual level, even though a good correlation was observed between PbB and porphyrin metabolism indices. From the alterations observed in ALA-D and PP values it was not possible to establish an association between degree of alteration and types of clinical symptoms in the different intoxication studies. At the end of EDTA treatment, a clinical improvement was observed in all cases studied but only in 5 cases was a reduction in PbB observed, to levels below 1.20 mol/l, which is accepted as a permissible limit for the general population; in 17 cases PbB remained at levels above the critical value for occupational lead poisoning (400 micrograms/l), although there was a decrease after treatment. The improvement observed in the indices of porphyrin metabolism at the end of treatment was only slight: significant variations were measured only for PbB. After treatment no association was observed between ALA-D and PP variations in erythrocytes and improvement in clinical symptoms; measurement of these indices therefore seems to be of little use in assessing the efficacy of the treatment. In spite of its limited diagnostic sensitivity during intoxication, measurement of ALA in urine could be useful to assess the efficacy of chelating therapy in subjects in whom the values are initially altered.
Petkova
V
V
Clinica di Malattie Professionali, Ospedale Facoltativo San Ivan Rilksi, Sofia, Bulgaria.
Adjarov
D
D
Pavlova
S
S
Naydenova
E
E
Kerimova
M
M
Kuneva
T
T
D000328:Adult; D000622:Aminolevulinic Acid / Q000652:urine; D004341:Drug Evaluation; D004492:Edetic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D004912:Erythrocytes / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D007855:Lead Poisoning / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000623:Porphobilinogen Synthase / Q000097:blood; D013997:Time Factors
D000622:Aminolevulinic Acid; D004492:Edetic Acid; D000623:Porphobilinogen Synthase
Valutazione dei primi risultati della terapia del saturnismo con EDTA.